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Abstract
Parasitic diseases plague billions of people among the poorest, killing millions annually, and causing additional millions of
disability-adjusted life years lost. Leishmaniases affect more than 12 million people, with over 350 million people at risk.
There is an urgent need for efficacious and cheap vaccines and treatments against visceral leishmaniasis (VL), its most severe
form. Several vaccination strategies have been proposed but to date no head-to-head comparison was undertaken to assess
which is the best in a clinical model of the disease. We simultaneously assayed three vaccination strategies against VL in the
hamster model, using KMPII, TRYP, LACK, and PAPLE22 vaccine candidate antigens. Four groups of hamsters were
immunized using the following approaches: 1) raw extracts of baculovirus-infected Trichoplusia ni larvae expressing
individually one of the four recombinant proteins (PROT); 2) naked pVAX1 plasmids carrying the four genes individually
(DNA); 3) a heterologous prime-boost (HPB) strategy involving DNA followed by PROT (DNA-PROT); and 4) a Control
including empty pVAX1 plasmid followed by raw extract of wild-type baculovirus-infected T. ni larvae. Hamsters were
challenged with L. infantum promastigotes and maintained for 20 weeks. While PROT vaccine was not protective, DNA
vaccination achieved protection in spleen. Only DNA-PROT vaccination induced significant NO production by macrophages,
accompanied by a significant parasitological protection in spleen and blood. Thus, the DNA-PROT strategy elicits strong
immune responses and high parasitological protection in the clinical model of VL, better than its corresponding naked DNA
or protein versions. Furthermore, we show that naked DNA coupled with raw recombinant proteins produced in insect
larvae biofactories –the cheapest way of producing DNA-PROT vaccines– is a practical and cost-effective way for potential
‘‘off the shelf’’ supplying vaccines at very low prices for the protection against leishmaniases, and possibly against other
parasitic diseases affecting the poorest of the poor.
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Introduction
Parasitic diseases are major causes of human disease and misery.
They plague billions of people among the poorest, killing millions
annually, and additionally causing millions of disability-adjusted
life years lost (DALY). New strategies are urgently needed for
diagnosis, treatment and prevention of these pathogens, however
the difficulty of cultivating parasites in vitro, their complex
organization and life cycle, coupled with its antigenic variability
are hampering the results [1].
Leishmaniases can serve as model for other parasitic diseases.
Leishmaniases are diseases caused by species of the kinetoplastid
parasite Leishmania spp. and transmitted by hematophagous
sandflies. Leishmaniases represent a major, although grossly
underestimated, health problem: over 350 million people are at
risk, with a worldwide prevalence of more than12 million cases.
The clinical presentation is dependent upon both the parasite
species and the host’s immune response. Visceral leishmaniasis
(VL) is the most severe form of the disease with deadly epidemics
that periodically flare up but go mostly unnoticed. VL has an
estimated annual incidence of 500 000, a 90% mortality rate if left
untreated, and accounting for around 70 000 deaths per year, thus
ranking second only to malaria for mortality and fourth for
morbidity amongst tropical parasitic diseases [2,3,4]. Leishmania
donovani causes anthroponotic VL, whereas L. infantum (syn. L.
chagasi) is the causative agent of the zoonotic form, with the
domestic dog as its main reservoir.
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The control of the disease, as it is the case for most parasitic
diseases, is almost confined to chemotherapy, but there are limited
number of drugs available, requiring long periods of administra-
tion, inducing serious side effects, prone to resistance development,
and not affordable for the poor [5]. Currently, it is widely accepted
that the concomitant immunity associated to resistance to both
human VL and canine leishmaniasis (CanL) is associated to a
skewed Th1-like immune response with an antigen-specific CD4+
T-cell population producing IFN-c, which in turns activates
macrophages to produce NO, the underlying molecule responsible
for the intracellular amastigote death [6,7]. In fact, the European
Medicines Agency has awarded marketing authorization for the
prophylaxis and early treatment of CanL to domperidone
(LeisguardH, Laboratorios del Dr. Esteve, Barcelona, Spain) [8],
an antidopaminergic drug that can act as a proinflammatory
cytokine able to skew immune response towards a Th1-like
immune response, with cell-mediated immunity (CMI) inducing
natural killer cell induction and macrophage activation. Thus,
vaccines have been proposed as major cost-effective tools [9,10]
and have been established as a high priority by the World Health
Organization (resolution EB118.R3, Geneva 05/07). However, no
vaccine against human VL has been marketed to date. Two
vaccines have granted marketing authorization against CanL in
Brasil –LeishmuneH (Pfizer Sau´de Animal, Sa˜o Paulo, Brasil) [11]
and Leish-TecH (Hertape Calier Sau´de Animal, Juatuba, Brasil)
[12]– and another one has just get a European registration –
CaniLeishH Virbac, Carros, France). However, the efficacy of
these vaccines remains controversial, particularly when compared
with those against viral and bacterial infections.
Several vaccination strategies against VL have been assayed
[13,14]. Killed vaccines have generally been immunogenic yet
ineffective. Recombinant protein-based vaccines have achieved
moderate protection in mice and dogs, but they often need to be
formulated with an adjuvant, which complicates the process for
getting marketing authorization, particularly in human medicine.
Naked DNA vaccines have also been tested reaching different
degrees of protection in rodents, but they have often proved
inadequate in providing protection in non-murine models [15].
The only two naked DNA vaccines assayed against L. infantum in
dogs were not protective [16,17]. In order to enhance inmuno-
genicity, DNA vaccines can be improved by the heterologous
prime-boost (HPB) strategy, which potentially allows for higher
degrees of immunity and protection. This strategy selectively
amplifies memory T cells specific for the vaccine antigen [18].
Prime-boost assays carried out against Leishmania with the antigen
LACK achieved protection in mice [19], but was only moderate in
dogs [16,20,21]. In contrast, prime-boost vaccination using CPA
and CPB antigens was highly protective in both mice [22] and
dogs [23]. A cocktail of different evolutionary conserved antigens
would probably provide the best protection against the parasite, as
suggested elsewhere [24].
We have shown that insect-derived recombinant proteins
produced in insect larvae used as living biofactories, even in its
raw form, are useful for diagnosis [25,26,27,28,29,30,31], includ-
ing that of leishmaniasis [32,33], and vaccination [34,35,36,37].
In this study, we used four evolutionarily conserved L. infantum
antigens –KMPII (kinetoplastid membrane protein-11, formerly
known as KMP-11), TRYP (tryparedoxin peroxidase, previously
known as TSA), LACK (L. infantum homologue of receptors for
activated C kinase), and PAPLE22 (potentially aggravating protein
of L. infantum)–, formerly shown to be potent B-cell and T-cell
immunogens in L. infantum-infected dogs [32], to simultaneously
compare the protection induced using three vaccination strategies:
naked plasmid DNA (DNA), raw insect-derived recombinant
protein (PROT), and HPB with naked plasmid DNA followed by
raw insect-derived recombinant protein (DNA-PROT). There are
several mouse-based models for modeling the immunity against
Leishmania, however vaccine studies against VL are hampered by
the lack of bio-models that accurately reflect the human disease,
being the best the golden hamster when experimental infection is
used, and the dog for natural infections [38]. Thus, we used the
golden hamster model of L. infantum infection, known to be the best
mimicking the outcome of this disease, characterized by parasite
visceralization, splenomegaly, cachexia, and progressive hyper-
gammaglobulinemia [39,40]. Susceptibility of the hamster to VL is
attributed to impaired macrophage effector function, as iNOS
transcription is relatively unresponsive to IFN-c, a finding also
reported in humans [41,42]. Potential drawbacks of the model are
that it uses outbred animals and suffers from lack of immunolog-
ical reagents and assays needed for the dissection of immune
responses [4,43].
Results
Safety
The first dose of protein vaccine was well tolerated, but the
second one induced transitory pruritus, which resolved within a
few hours. This occurred for both wild-type (Ni) and recombinant
protein extracts. DNA vaccination was well tolerated, and adverse
reactions were not noticed.
Immunogenicity
Specific seroreactivity to crude total L. infantum antigen (CTLA)
was not detected before challenge in any vaccinated hamster.
Seroreactivity against recombinant antigens could not be evalu-
ated in groups immunized with T. ni protein extracts –PROT,
DNA-PROT, and control (C)– due to the non-specific responses
induced against larva antigens. In the DNA group, specific
responses were not detected against the recombinant antigens
KMPII, TRYP, or PAPLE22, with only one hamster showing
specific anti-rLACK antibodies.
In vitro infected macrophages from DNA-PROT vaccinated
hamsters produced a significantly higher quantity of NO than
those from the C group (Mann-Whitney U; P= 0.029), while no
differences were observed between DNA or PROT groups and the
C group (Figure 1). No significant differences were found between
the number of amastigotes infecting macrophages from the
vaccinated groups and the C group at 72 h post-in vitro infection
(Mann-Whitney U; P . 0.050 for all comparisons).
Parasitological Protection
The descriptive statistical analysis (Figure 2) identified an
extreme outlier in the blood parasite load from the DNA-PROT
group (Grubbs’ test; P= 0.026 and 3.06 the interquartile range
outside the central box [44]), which was excluded in the
subsequent inferential analysis. When compared to the C group,
PROT vaccine was not protective neither in spleen (Mann-
Whitney U; P= 0.818) nor in blood (Mann-Whitney U; P= 0.179).
In contrast, DNA vaccine achieved significant parasitological
protection in spleen (Mann-Whitney U; P= 0.015), but was not
protective in blood (Mann-Whitney U; P= 0.792). Finally, DNA-
PROT vaccine induced significant parasitological protection in
spleen (Mann-Whitney U; P= 0.030) and highly significant
parasitological protection in blood (Mann-Whitney U; P ,
0.001). The results are shown in Figure 2.
One hamster from the DNA group and another one from DNA-
PROT group showed absolute sterile protection both in blood and
spleen.
Leishmania Vaccine: Comparison of Strategies
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Specific Immune Response Induced Upon L. infantum
Challenge
Concentration of specific anti-L. infantum antibodies in hamsters
from the DNA and PROT groups were not significantly different
to those from the C group (Mann-Whitney U; P . 0.050 for both
comparisons). Conversely, the DNA-PROT group produced
significantly lower anti-CTLA antibody concentrations than the
C group (Mann-Whitney U; P= 0.004). The results are shown in
Figure 3. The concentration of antibodies against CTLA
significantly correlated with the parasite load both in blood
(Spearman’s r; P , 0.001) and spleen (Spearman’s r; P , 0.001).
Seroreactivity against recombinant antigens could not be
evaluated in the PROT and DNA-PROT groups due to the
antibody responses induced against larva proteins. In the DNA
group, one hamster showed antibodies against rKMPII, rLACK,
and rPAPLE22, and another one developed antibodies against
rLACK. Seroreactivity against rTRYP was not detected.
Histopathology
Findings compatible with leishmaniasis –follicular hyperplasia,
mononuclear inflammatory infiltrate in the periportal areas, and
hyperplasia of Kupffer cells in the sinusoids– were milder in the
DNA-PROT group in relation to the C group. Those hamsters
achieving absolute sterile protection, both in blood and spleen,
showed no histopathological abnormalities in the spleen or liver.
No histological abnormalities were found elsewhere.
Discussion
We used the preclinical golden hamster model of VL for a head-
to-head simultaneous comparison of the protective efficacy of
three vaccination strategies –based on the antigens KMPII,
TRYP, LACK, and PAPLE22– against L. infantum infection: raw
insect-derived recombinant protein (PROT), DNA, and HPB
DNA-PROT.
In spite of the fact that vaccination with recombinant proteins
has been described as moderately effective against L. infantum
infection in rodents [45,46], the immunization of hamsters with
crude rKMPII, rTRYP, rLACK, and rPAPLE22 expressed in T.
ni larvae did not achieve parasitological protection, and we could
not detect specific CMI. Raw protein extracts of larvae include
remains of baculovirus and it has been shown to stimulate
proinflamatory cytokines involved in the stimulation and mainte-
nance of Th1 cellular immune responses [47], including those
against Leishmania. This stimulation occurs through the MyD88-
TLR9 pathway, being TLR9 the innate receptor for unmethylated
CpG motifs –present in the baculoviral DNA–, that are considered
pathogen-associated molecular patterns and responsible for the
immunostimulatory Type I proproinflamatory response [48]. In
this way, the intrinsic immunostimulatory property of baculovirus
may alleviate the requirement of traditional adjuvants added to the
vaccine formulations [49,50,51]. In our case this stimulation
appears not to be enough, and the lack of traditional adjuvants
might explain the failure to induce a Th1 response [24]. However,
few adjuvants have been approved for human vaccines, and they
currently appear inadequate to confer protection against other
intracellular parasitic diseases [52]. In contrast, other vaccines
using raw insect-derived recombinant proteins yielded successful
results against viral diseases [53], even in the absence of an
adjuvant [34] . This fact probably reflects the strong CMI required
for protection against intracellular parasites, or a deleterious effect
of some of the vaccine antigens used in our assay. KMPII [54],
LACK [55], and PAPLE22 [56] elicit human production of IL-10,
an anti-inflammatory cytokine capable of inhibiting synthesis of
Th1-like cytokines, which has also been described in infected
hamsters [57].
Figure 1. Box plot displaying minimum, first quartile, second quartile (median), third quartile, maximum, and outliers of the
production of NO achieved using different vaccination strategies. Production of NO by Leishmania infantum–infected macrophages
obtained from hamsters vaccinated with KMPII, TRYP, LACK, and PAPLE22 in the form of raw extracts of Trichoplusia ni larvae producing recombinant
proteins (PROT; n = 4), naked plasmid (DNA; n = 4), both vaccines combined in a prime-boost strategy (DNA-PROT; n = 4), and in control hamsters (C;
n = 4). Each sample was analyzed in triplicate. (*P= 0.029).
doi:10.1371/journal.pone.0051181.g001
Leishmania Vaccine: Comparison of Strategies
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DNA vaccines have proven capable of stimulating antibody
production, as well as CD4+ and CD8+ T CMI [58]. In our study,
the DNA vaccine induced antibodies against rLACK in one
hamster, but antibodies against the other vaccine antigens were
not detected, as it has been reported for other DNA candidates
[59]. Despite the lack of parasitological protection in blood, the
significant parasitological protection in spleen –that achieved
sterility in some animals– suggests that some degree of CMI
response was induced, although not enough for significant NO
production. DNA vaccine could have a deleterious effect on
aberrant B-cell proliferation and antibody production associated
with disease [39], as it prevented hyperplasia of the lymphoid
follicles after challenge.
HPB vaccination using raw insect-derived recombinant proteins
after DNA achieved almost full parasitological protection in blood
and spleen, reaching sterility in some individuals. This protection
was associated with significant production of NO in the
macrophages, indicative of effective T-cell mediated anti-L.
infantum activity. Other studies have described an association
between vaccine protection and levels of NO production [60] or
Figure 2. Parasite load achieved using different vaccination strategies. Parasite load in spleen (relative, fold more DNA copies than the
calibrator) and parasite load in blood (parasites/mL) 20 weeks after Leishmania infantum challenge in hamsters vaccinated with KMPII, TRYP, LACK,
and PAPLE22. C: Control (n = 6); PROT: Raw extracts of Trichoplusia ni larvae producing recombinant proteins (n = 6); DNA: Naked plasmid DNA (n = 6);
DNA-PROT: Both vaccines combined in a prime-boost strategy (n = 5). Each sample was analyzed in triplicate.
doi:10.1371/journal.pone.0051181.g002
Leishmania Vaccine: Comparison of Strategies
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iNOS expression [61] in hamster macrophages. Despite the
relative unresponsiveness of iNOS transcription to IFNc in the
hamster [42], other cytokines, such as IL-1, TNF, IFNa, or IFNb
might induce NO production and protection [62]. Moreover, a
lower parasite-specific humoral response was observed in the
DNA-PROT group in relation to the C group after challenge.
This phenomenon –also described in hamsters vaccinated with
PAPLE22 DNA [63] and in other protective vaccines against VL
in hamsters [61] and dogs [12,21]– might be due to a redirection
of the Th2-like response towards a Th1-like response and/or to
the lower antigenic stimulation caused by lower parasite loads. In
this sense, our results showed a positive correlation between
parasite load in spleen and blood samples and the L. infantum-
specific humoral response, as previously described in hamsters
[40]. The DNA-PROT vaccine also prevented certain histopath-
ological alterations in spleen and liver that have been attributed to
leishmaniasis in hamsters and dogs [40,64].
Attempts to enhance the protective immune responses against
experimental murine leishmaniasis have been successful using
HPB vaccination strategies based on successive administration of
different DNA vector vaccines [65,66]. A number of antigen
candidates have been assayed on the murine model of VL in a
HPB approach based on DNA followed by protein produced using
traditional cell-culture technology, such as, ORFF [67], CPs [22],
and LACK [19]. Moreover, comparative vaccine potential of
DNA, protein, and HPB vaccination was evaluated against
leishmaniasis in the murine model [68,69]. Unfortunately,
experimental models often lack consistency with clinical settings
[70,71], thus being the major challenge the translation of results
from animal bio-models to human disease and the transition from
the laboratory to the field [72]. Because of the many analytical
tools available, the murine model of VL is an excellent one to
dissect the immunological bases but, when research is focused on
the disease, it is a very poor model because in most situations they
clear infection from both spleen and liver providing very little
medical translational information. Conversely, the hamster model
of VL has very little tools for studying immunity being an
incomplete model for immunological studies, but it reproduces
with high fidelity the clinical human disease [39,73]. Thus, when
studying the disease, not their immunological bases –that very
often do not translate directly into clinical disease–, the hamster
model is very robust and, by far, better and preferable over the
murine one, because of the added value of the high medical
translational information obtained.
To the authors’ knowledge, this is the first head-to-head
simultaneous comparison between naked DNA, raw insect-derived
recombinant protein, and HPB strategies performed using a
reliable and robust clinical model of VL. Our results show that the
HPB strategy with naked DNA and raw insect-derived recombi-
nant proteins –rKMPII, rTRYP, rLACK, and rPAPLE22– elicitis
a strong CMI response and parasitological protection against L.
infantum, better than that obtained with either the naked DNA or
protein vaccines used alone. Last but not least, our results
demonstrate that using naked DNA –the cheapest way of
obtaining DNA vaccines– coupled with raw recombinant proteins
produced in insect larvae biofactories –capable of producing large
quantities of recombinant protein per biomass unit at low
production costs and easy to scale-up [36]– is a practical and
cost-effective way for ‘‘off the shelf’’ supplying vaccine doses at a
very low price for the protection against leishmaniases, and
possibly against other parasitic diseases affecting the poorest of the
poor.
Materials and Methods
Ethics Statement
The experimental design and analyses have been planned to
ensure cost-benefit in the number of animals used and according
to the Three Rs [74,75]. The experimental procedures involved in
this research have been approved by the Ethics Committee on
Figure 3. Seroreactivity achieved using different vaccination strategies. Seroreactivity against crude total Leishmania antigen (CTLA) 20
weeks after Leishmania infantum challenge in hamsters vaccinated with KMPII, TRYP, LACK, and PAPLE22. C: Control; PROT: Raw extracts of
Trichoplusia ni larvae producing recombinant proteins; DNA: Naked plasmid DNA; DNA-PROT: Both vaccines combined in a prime-boost strategy. The
dotted line shows the cut-off value.
doi:10.1371/journal.pone.0051181.g003
Leishmania Vaccine: Comparison of Strategies
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Animal and Human Research of the Universitat Auto`noma de
Barcelona (CEEAH 662), in accordance with the ethical and legal
requirements (5/1995/Generalitat de Catalunya, 214/1997/
Generalitat de Catalunya, Real Decreto 1201/2005, 86/609/
CEE, 91/628/CEE and 92/65/CEE) concerning the use of
animals in research, and registered by the Department de Medi
Ambient of the Generalitat de Catalunya (DMAH 3922).
Gene Cloning and DNA Vaccine Construction
Gene cloning was performed as previously described [17]. The
primers used to amplify the coding sequences of the KMPII, TRYP,
and LACK genes have been described elsewhere [17] and the
coding region of PAPLE22 (GenBank accession number
AF123892) was amplified using forward 59-
GGCCACTTCTCTCTTCTCCA-39 and reverse 59-
CTTGCCACATACACCAATCG-39 primers. The coding se-
quences of each gene were cloned separately into the pVAX1TM
vector (InvitrogenTM, Carlsbad, CA, USA). Large-scale plasmid
preparations were performed using an EndoFreeH Plasmid Giga
Kit (QiagenH, Valencia, CA, USA) according to the manufactur-
er’s instructions.
Recombinant Proteins and Protein Vaccine Production
Recombinant proteins were obtained in baculovirus-infected
Trichoplusia ni larvae as described elsewhere [32,33]. Wild-type
baculovirus was used to obtain the control raw protein extract (Ni
antigen) for vaccination and ELISA. The concentrations of specific
recombinant proteins in the raw T. ni extracts were 1% for
recombinant KMPII protein (rKMPII), 0.5% for rTRYP, 2% for
rPAPLE22, and 5% for rLACK. Antigenic characterization of the
recombinant proteins has been explained elsewhere [32,33].
Experimental Design, Animals and Immunizations
Forty-four ten-week-old male golden hamsters (Mesocricetus
auratus, outbread strain Han:AURA) purchased from a commer-
cial source (Centre d’Elevage Rene´ Janvier, Le Genest-Saint-Isle,
France) were used for this study. The animals, housed in micro-
filter cages at animal biosafety level 2 facilities, were kept and
handled by a veterinarian.
Forty hamsters were randomly assigned to four equally sized
experimental groups: protein vaccine (PROT), naked DNA
vaccine (DNA), prime-boost vaccine (DNA-PROT), and control
(C). One hamster from the DNA-PROT group died during the
acclimatizing period and was not substituted. All groups were
handled in parallel so that infection inoculum was the same and
administered at the same time, as it was the case for vaccinations
and euthanasia. Samples from four additional hamsters that were
neither vaccinated nor infected (NN) were used as controls for the
different techniques.
The PROT group received 2 intraperitoneal doses of a mixture
of raw larvae extracts containing 5 mg of each recombinant protein
in 200 mL of sterile saline solution. The DNA group received 3
intramuscular doses of 100 mg of each plasmid construction in
100 mL of sterile saline solution (50 mL into each tibialis cranialis
muscle). The DNA-PROT group received 3 doses of DNA
vaccine, followed by 2 doses of protein vaccine using the same
protocols as for the DNA group and the PROT group. Finally, the
C group received 3 doses of pVAX1TM without insert (400 mg) in
100 mL of sterile saline solution, followed by 2 doses of Ni antigen,
using the equivalent amount of total protein as in the DNA-PROT
group. The interval between immunizations was 2 weeks. The
safety of the vaccine prototypes was assessed at 1 h, 4 h, 24 h,
48 h, and 72 h after each vaccination by close observation and
clinical examination of the animals. No adjuvants were used in
order to not to interfere with the actual protective response of the
different vaccination strategies and to allow comparisons.
Valid surrogate markers of protection against human
leishmaniasis and in clinical bio-models are still lacking. The
most widely used measure of vaccine potential has been to
monitor anti-Leishmania immune responses, either humoral or
cellular, over time but nucleic acid detection is an established
method for detection of Leishmania parasite in blood and other
tissues [38]. As explained by WHO guidelines [76], confirma-
tion of infection by very sensitive methods such as PCR or
culture represent a very early end-point of the development of
the disease [77]. Thus, primary outcome measures were
differences between groups in parasite load and in NO
production, the main functional effector responsible for killing
Leishmania and for controlling the infection [78]. Secondary
outcomes were differences in specific humoral immune response,
parasite killing, and histopathology.
Parasites and Challenge
Two weeks after the last immunization, four hamsters from each
vaccine group were euthanized to evaluate the immunogenicity of
each vaccination schedule. The remaining hamsters were
challenged with an intraperitoneal injection of 16 107 stationary
promastigotes of L. infantum (strain MCAN/ES/92/BCN-83/
MON-1), clinically evaluated once a week for the presence of signs
compatible with leishmaniasis, and euthanized 20 weeks after
experimental infection. Parasites –kindly provided by Dr. M.
Ga´llego, Grup de Parasitologia Clı´nica, Universitat de Barcelona,
Spain– were obtained from a naturally infected dog that had not
received any treatment and were passaged through hamsters in
order to retain their full virulence.
Necropsy and Tissue Sampling
Hamsters were anesthetized by a 100 mL intramuscular
injection containing 42.5 mg?mL21 ketamine, 9.5 mg?mL21
xylazine, and 1.5 mg?mL21 acepromazine. Then, a 5 mL sample
of intracardiac blood was collected and the animals were
euthanized using CO2.
Peritoneal macrophages were collected by intraperitoneal
injection of cold Gibco Dulbecco’s Modified Eagle Medium
(DMEM) (InvitrogenTM, Carlsbad, CA, USA) supplemented with
5% (v/v) FCS and 1% (w/v) EDTA, only from hamsters
euthanized after vaccination.
A sample of spleen tissue was collected and snap-frozen in liquid
nitrogen. Spleen size was roughly estimated at necropsy as length
6 width (cm2). Normal spleen size range was estimated on the
basis of the results from hamsters in the NN group and calculated
as the mean area 6 3 SD. Spleens larger than 2.7 cm2 were
considered to be abnormally enlarged.
Samples of spleen, liver, and kidney were collected and fixed in
buffered 10% formaldehyde solution.
Crude Total Antigen and Recombinant Antigen-based
ELISA
The specific humoral immune response against CTLA and
recombinant L. infantum antigens was measured by ELISA as
previously described [32,79].
For recombinant antigen-based ELISAs, each serum sample
was tested against each raw protein larva extracts containing
rKMPII, rTRYP, rLACK, rPAPLE22, and their corresponding
control Ni antigen prepared at the same concentration in the same
plate. For CTLA-ELISA, plates were coated with 2 mg of CTLA
per well. Working dilutions for sera were 1:10 (recombinant
Leishmania Vaccine: Comparison of Strategies
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antigen-based ELISAs) or 1:400 (CTLA-ELISA). Anti-hamster
IgG antibody (Sigma-AldrichH, St. Louis, MO, USA) diluted
1:1000 was used as a secondary antibody. A known positive serum
used as calibrator was included in all plates, and plates with
interassay variations $ 10% were ruled out. The cut-off values for
both types of ELISA were established on the basis of optical
densities obtained from the NN group and calculated as the mean
+ 3 SD, resulting in 0.122 for CTLA, 0.266 for rKMPII, 0.050 for
rTRYP, 0.284 for rLACK, and 0.376 for rPAPLE22.
ELISA results were expressed as optical densities (OD). For
those using recombinant antigens, absorbances were corrected by
subtracting the absorbance achieved by the serum on the control
antigen Ni extract from that achieved by the protein larva raw
extract containing specific recombinant antigen.
Quantification of NO Production and Parasite Killing by
Macrophages Infected in vitro
Peritoneal macrophages were harvested at 26105 per well in a
16-well glass Lab-TekTM-Chamber SlideTM System (Nalge Nunc
International, Rochester, NY, USA). In vitro infection was
performed with stationary-phase promastigotes of L. infantum
(MCAN/ES/92/BCN-83/MON-1) at a parasite:macrophage
ratio of 7:1 for 4 h at 37uC in 5% CO2. Non-internalized
parasites were removed by gentle washing with pre-warmed PBS,
and infected macrophages were then cultured in Gibco DMEM
without Phenol Red (InvitrogenTM, Carlsbad, CA, USA) supple-
mented with 5% (v/v) FCS for 72 h. Supernatants were then
collected and stored at 280uC, and slides were Giemsa-stained.
Culture supernatants were analyzed for their NO concentra-
tions using the Griess reaction by measuring combined oxidation
products of NO (NO2
2 and NO3
2) after reduction with nitrate
reductase in a Colorimetric Assay (Cayman Chemical Company,
Ann Arbor, MI, USA). The number of amastigotes per 100
macrophages was determined by microscopic examination of
Giemsa-stained slides.
Real-time PCR Amplification of L. infantum DNA from
Spleen and Blood Samples
L. infantum DNA was specifically detected and quantified as
described elsewhere using the TaqmanH real-time PCR (qPCR)
(Applied BiosystemsTM, Foster City, CA, USA) targeting con-
served DNA regions of the kinetoplast minicircle DNA, and the
eukaryotic 18S RNA Pre-Developed TaqMan Assay Reagents
(Applied Biosystems, Foster City, CA, USA) as internal reference
gene. For spleen, relative quantification was performed by the
22DDCt method [80] using as calibrator the sample showing the
lowest DCt and results expressed as x-fold more DNA copies than
this calibrator sample [81]. For blood, quantification was
performed by the 22DDCt method [80] using as calibrators spiked
samples with a known number of parasites/well, thus allowing
determining the number of parasites in any PCR sample,
independently of the amount of DNA added or the presence of
inhibitors, and results expressed as parasites/mL [82].
Histopathology
Samples of liver, spleen and kidney were embedded in paraffin,
and sections were stained by hematoxylin and eosin for
histopathological study with high-power light microscopy at6400.
Statistical Analysis
Two-tailed non-parametric techniques were used throughout
the study. Statistical significance for a posteriori comparisons was
corrected for multiple simultaneous comparisons employing a
rough false discovery rate [83]. All analyses were carried out using
SPSS v.14.0 (SPSS Inc, Chicago, IL, USA).
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